Article

The aim of this study was to elucidate clinical trial efficacy,
safety, and dosing practices of abobotulinumtoxinA (ABO) treatment in adult
patients with upper limb spasticity (ULS). METHODS: A systematic literature
review was performed to identify randomized controlled trials and other
comparative clinical studies of ABO in the treatment of adult ULS published in
English between January 1991 and January 2013. Medical literature databases
(PubMed, Cochrane Library, and EMBASE) were searched, and a total of 295 records
were identified. Of these, 12 primary publications that evaluated ABO for the
management of ULS were included in the final data report. SYNTHESIS: Total ABO
doses ranged between 500 and 1500 U for ULS. Most of the studies in ULS showed
statistically significant benefits (reduction in muscle tone based on Ashworth
score) of ABO vs. placebo. Statistical significance was reached for most
evaluations of spasticity using the Modified Ashworth Scale. Statistically
significant effects on active movement and pain were demonstrated, albeit less
consistently. ABO was generally well tolerated across the individual studies;
most adverse events reported were considered unrelated to treatment. Adverse
events considered associated with ABO treatment included fatigue, tiredness, arm
pain, skin rashes, flu-like symptoms, worsening of spasm, and weakness.
CONCLUSIONS: On the basis of data extracted from 12 randomized clinical studies,
a strong evidence base (9/12 studies) exists for the use of ABO to reduce ULS
caused by stroke.

Langue : ANGLAIS